- SEK40.57bn
- SEK36.61bn
- SEK2.27bn
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat
Sweden's Camurus Q2 revenue beats estimates on Buvidal and Brixadi demand
Brief: Camurus Reiterates Outlook For 2026
Crinetics will get more time after FDA setback for Camurus' rival drug, Piper Sandler says
Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback
Camurus slides after FDA rejection of Oclaiz delays launch
Brief: FDA Issues Complete Response Letter For Camurus CAM2029 NDA For Acromegaly
Brief: Camurus Announces Expansion Of Lilly Collaboration
Camurus falls as lower drug sales drive Q1 miss
Sweden's Camurus Q1 revenue misses; reiterates 2026 financial outlook
Brief: Camurus Keeps 2026 Revenue Outlook Unchanged
Europe Research Roundup: Antofagasta, Danske Bank, Munich Re
Europe Research Roundup: Antofagasta, Danske Bank, Munich Re
Europe Research Roundup: ABN Amro Bank ,Kering, SGS
Camurus hits bottom of STOXX on 'big' Q4 miss
Brief: Camurus Proposes No Dividend To Be Paid For 2025